This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to ...

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

The FDA has approved cosibelimab, a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer ... constipation, nausea, headache, rash, reactions where the ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC ... The most common adverse ...

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).

FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not ...

Upstream Bio is leveraging TSLP targeting for respiratory disorders treatment, with IPO funds and upcoming Chronic ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive ...

New research reveals significant differences in gene expression related to metabolism, inflammation and cardioprotection in ...

In milder cases this can be accomplished by relatively simple means: a limited cutaneous rash may be amenable to treatment with topical glucocorticoids, and mild to moderate arthritis or pleurisy ...